Fennec Pharmaceuticals Posts Strong Q2 Growth on PEDMARK Demand Surge — Fennec Pharmaceuticals Inc.

Event summary

Fennec Pharmaceuticals reported Q2 2026 net product sales of $17.1 million, up 78% year-over-year.
Non-GAAP adjusted EBITDA reached $2.8 million, marking the company's seventh consecutive quarter of growth.
ASCO 2026 presented real-world evidence reinforcing PEDMARK's integration into patient care without compromising cisplatin's antitumor activity.
Commercial expansion efforts drove record demand in Q2, with momentum carrying into Q3.

The big picture

Fennec Pharmaceuticals' strong Q2 performance underscores the growing demand for PEDMARK as a critical adjunct therapy in cisplatin-based chemotherapy. The company's ability to scale commercial operations while maintaining financial discipline positions it favorably in the competitive oncology space, where real-world evidence and expanded clinical utility are increasingly driving adoption.

What we're watching

Commercial Scaling: Whether Fennec can sustain its rapid commercial growth trajectory as it expands its sales organization and targets new patient populations.
Clinical Expansion: The pace at which investigator-sponsored studies will broaden PEDMARK's clinical utility in adolescent and adult populations.
Financial Discipline: How the company balances increased selling and marketing expenses with its path to profitability.